Hot Investor Mandate 2: Korea-based Pharma Invests In Cardio, Diabetes, CNS and Respiratory Drugs

25 Feb

A South Korea-based pharmaceutical company is interested in forming strategic partnerships with biopharmaceutical companies that are interested in entering the Korean market. The structure of the partnership includes in-licensing, co-marketing, co-promotion, join-ventures, and equity investment. The company is actively seeking new partnership opportunities.

The firm is currently seeking products in the following therapeutic areas: Cardiovascular disorder such as hypertension; Endocrinology disorder such as Type I, II Diabetes & Diabetic complications; CNS disorder such as Depression, Schizophrenia, Anxiety disorder, Insomnia, Alzheimer’s disease, Parkinson’s disease and Various pain types; Ophthalmic disorder; Respiratory disorder; Oncology disorder; Degenerative/Age-related diseases. The company prefers to invest in products that have attained human proof of concept, and is also interested in partnering with companies that have products on the market.

The firm will partner with companies from around the world that are interested in entering the Korean market.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: